Beam Therapeutics Secures $500 Million Credit Facility

Beam Therapeutics ( (BEAM) ) has shared an update.

On February 24, 2026, Beam Therapeutics reported fourth-quarter and full-year 2025 financial results, showing cash, cash equivalents and marketable securities of $1.25 billion at year-end, up from $850.7 million a year earlier, alongside higher annual R&D spending of $409.6 million. The company reiterated 2026 milestones across its liver and hematology franchises, including updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency in the first quarter and initial clinical data for BEAM-301 in glycogen storage disease type Ia later in the year.

Beam expanded its liver-targeted portfolio with BEAM-304, a new base-editing program for phenylketonuria that aims to durably correct PAH gene mutations via lipid nanoparticle delivery, with an IND filing planned in 2026 and a Phase 1/2 trial designed to address multiple mutation-specific editors. In hematology, updated Phase 1/2 BEACON data continued to support a potentially best-in-class profile for risto-cel in sickle cell disease, with manufacturing for all clinical doses completed and a U.S. BLA submission targeted as early as year-end 2026.

To support its late-stage pipeline, Beam on February 24, 2026, entered a senior secured credit facility of up to $500 million with Sixth Street, providing long-term, non-dilutive capital linked to risto-cel regulatory and commercial milestones and extending expected cash runway into mid-2029. The facility includes $100 million funded at closing, a further $300 million tied to specified achievements, and an additional $100 million available by mutual agreement, and is secured by substantially all company assets, with covenants around liquidity, indebtedness, and commercialization of risto-cel.

Beam also highlighted the December 2025 transition of its four-year in vivo base-editing collaboration with Pfizer, under which Pfizer opted for an exclusive worldwide license to a liver-targeted development candidate using Beam’s LNP delivery, assuming full development and commercialization control. Beam remains eligible for milestone payments and retains an option, after Phase 1/2, to co-develop and co-commercialize globally under a profit- and cost-sharing arrangement, reinforcing the platform’s external validation and potential future revenue streams.

The most recent analyst rating on (BEAM) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Spark’s Take on BEAM Stock

According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.

The score is held back primarily by weak financial performance (declining revenue, very large losses, and negative cash flows). Technicals are constructive with strong trend and positive MACD, but overbought RSI adds near-term risk. Corporate events are a meaningful positive (extended runway and regulatory/clinical progress), while valuation support is limited due to losses and a negative P/E.

To see Spark’s full report on BEAM stock, click here.

More about Beam Therapeutics

Beam Therapeutics Inc., based in Cambridge, Mass., is a biotechnology company focused on developing precision genetic medicines using base editing technology. Its pipeline includes liver-targeted genetic disease programs such as BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type Ia, as well as hematology candidates including risto-cel for sickle cell disease.

Average Trading Volume: 1,806,230

Technical Sentiment Signal: Buy

Current Market Cap: $2.8B

For a thorough assessment of BEAM stock, go to TipRanks’ Stock Analysis page.